Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/12034754251336199 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Androgen therapy in midlife and older women: a position statement of the Latin American Association of Gynecological Endocrinology (ALEG).
Climacteric
September 2025
Escuela de Postgrado en Salud, Universidad Espíritu Santo, Samborondón, Ecuador.
Objective: Androgens have been prescribed to alleviate symptoms in midlife women, but evidence regarding benefits and risks remains limited, with no clearly established indications for Testosterone therapy. In many Latin American countries, Testosterone is prescribed without specific guidelines, making it difficult to identify patients who might benefit. This position statement aims to summarize evidence and provide a Latin American perspective on androgen therapy in midlife and older women.
View Article and Find Full Text PDFPeginterferon-alpha-2a add-on to treatment with siRNA JNJ-73763989 in virologically suppressed chronic hepatitis B: The phase II PENGUIN study.
JHEP Rep
October 2025
Janssen Pharmaceutica NV, Beerse, Belgium.
Background & Aims: Previous studies showed that combination treatment with short interfering RNA JNJ-73763989 (JNJ-3989) ± capsid assembly modulator bersacapavir (JNJ-56136379) and nucleos(t)ide analogs (NAs) was well tolerated by patients with chronic HBV (CHB), with JNJ-3989 dose-dependent reductions in viral markers, including HBsAg. The open-label, single-arm phase IIa PENGUIN study (NCT04667104) evaluated this regimen plus pegylated interferon alpha-2a (PegIFN-α2a) in patients with virologically suppressed CHB.
Methods: Patients who were either HBeAg-positive or -negative virologically suppressed and taking NAs were included; all received JNJ-3989 ± bersacapavir for 24 weeks (some either did not start or discontinued bersacapavir as a result of protocol amendment) with PegIFN-α2a added during the final 12 weeks of treatment.
Apremilast treatment of immune-mediated inflammatory skin diseases: a narrative review.
Front Pharmacol
August 2025
Department of Dermatology, Zhongshan Second People's Hospital, Zhongshan, Guangdong, China.
Novel therapeutic approaches on molecular pathways are being developed to treat inflammatory and autoimmune cutaneous dermatoses. Apremilast is an orally administered small-molecule phosphodiesterase 4 (PDE4) inhibitor that upregulates intracellular cyclic 3',5'-adenosine monophosphate (cAMP) levels to mediate a large array of proinflammatory cytokines as well as exerts its anti-inflammatory functions and therapeutic efficacy in skin diseases rather than an immunosuppressive mode of action. Early-phase clinical trials have demonstrated its favorable efficacy such that the United States Food and Drug Administration (USFDA) has approved its use for the treatment of psoriasis, psoriatic arthritis, and Behçet's syndrome.
View Article and Find Full Text PDFBiofeedback therapy using Cerebri for the prevention of migraine attacks in adults with episodic migraine (BioCer): a randomized, wait-list controlled trial - the study protocol.
F1000Res
September 2025
Norwegian Centre for Headache Research (NorHead), Norwegian University of Science and Technology, Trondheim, Norway.
Introduction: Biofeedback is a non-pharmacological treatment option valued for its minimal risk of adverse events and offers a safe alternative for individuals seeking preventive care for migraine. Despite level A evidence for migraine prevention, biofeedback treatment is still unavailable to most patients. We developed a novel medical device (Cerebri) for multimodal biofeedback treatment that omits the need for healthcare personnel involvement.
View Article and Find Full Text PDFEndometrial thickness and pathology in postmenopausal women with bleeding on transdermal 17β-estradiol plus body-identical progesterone.
Arch Gynecol Obstet
September 2025
Faculty of Population Health Sciences, EGA Institute for Women's Health, University College London, London, WC1E 6AU, UK.
Objective: The primary objective was to explore the relationship between endometrial thickness and transdermal 17β-estradiol/micronised progesterone dose in postmenopausal women with unscheduled bleeding on menopausal hormone therapy (MHT). The prevalence of endometrial pathology was also assessed.
Methods: Retrospective analysis of a consecutive case series.